Patents by Inventor Mark Winderlich

Mark Winderlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib
    Patent number: 9765152
    Abstract: A method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody and bortezomib or carfilzomib is disclosed.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 19, 2017
    Assignee: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL
    Publication number: 20160222127
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 4, 2016
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Combinations and uses thereof
    Patent number: 9289490
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: March 22, 2016
    Assignee: MorphoSys AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • COMBINATIONS AND USES THEREOF
    Publication number: 20150017160
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Applicant: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
    Patent number: 8877899
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: November 4, 2014
    Assignee: Morphosys AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD
    Publication number: 20140255427
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: August 14, 2012
    Publication date: September 11, 2014
    Applicant: MorphoSys AG
    Inventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
  • Combination therapy with an anti-CD19 antibody and a purine analog
    Publication number: 20140227277
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: August 14, 2012
    Publication date: August 14, 2014
    Applicant: MorphoSys AG
    Inventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
  • Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL
    Publication number: 20130302318
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: September 26, 2011
    Publication date: November 14, 2013
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson